Fulgent Genetics Presents Updated Data at ASCO Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 01 2026
0mins
Source: Newsfilter
- Clinical Trial Data Update: Fulgent Genetics presented updated data on FID-007 in combination with cetuximab at the 2026 ASCO Annual Meeting, revealing a 61.9% objective response rate in patients with recurrent or metastatic head and neck squamous cell carcinoma, indicating significant clinical activity in this target population.
- Survival Metrics: As of the April 16, 2026 data cutoff, the median progression-free survival was 6.7 months, median duration of response was 7.4 months, and one-year overall survival was 63.4%, providing crucial support for the clinical application of FID-007 and potentially altering treatment standards.
- Future Research Plans: Fulgent plans to conduct a Phase 3 study to further validate the efficacy and safety of the FID-007 and cetuximab combination, which may offer new hope for patients lacking effective second-line treatment options and holds significant market potential.
- Technological Platform Advantage: Fulgent's therapeutic development business focuses on developing cancer drugs using a novel nanoencapsulation and targeted therapy platform designed to improve therapeutic windows and pharmacokinetic profiles, highlighting the company's strategic transformation and innovation capabilities in precision medicine.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FLGT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FLGT
Wall Street analysts forecast FLGT stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 18.780
Low
30.00
Averages
32.50
High
35.00
Current: 18.780
Low
30.00
Averages
32.50
High
35.00
About FLGT
Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Fulgent Genetics Presents Updated Data at ASCO Meeting
- Clinical Trial Data Update: Fulgent Genetics presented updated data on FID-007 in combination with cetuximab at the 2026 ASCO Annual Meeting, revealing a 61.9% objective response rate in patients with recurrent or metastatic head and neck squamous cell carcinoma, indicating significant clinical activity in this target population.
- Survival Metrics: As of the April 16, 2026 data cutoff, the median progression-free survival was 6.7 months, median duration of response was 7.4 months, and one-year overall survival was 63.4%, providing crucial support for the clinical application of FID-007 and potentially altering treatment standards.
- Future Research Plans: Fulgent plans to conduct a Phase 3 study to further validate the efficacy and safety of the FID-007 and cetuximab combination, which may offer new hope for patients lacking effective second-line treatment options and holds significant market potential.
- Technological Platform Advantage: Fulgent's therapeutic development business focuses on developing cancer drugs using a novel nanoencapsulation and targeted therapy platform designed to improve therapeutic windows and pharmacokinetic profiles, highlighting the company's strategic transformation and innovation capabilities in precision medicine.
See More
Fulgent Genetics Under Investigation for Securities Violations
- Financial Performance Disclosure: Fulgent Genetics reported its 2025 fiscal year revenue at approximately $322.7 million on February 27, 2026, which slightly missed the updated guidance, indicating pressure in market competition.
- Quarterly Revenue Decline: The company's fourth-quarter revenue showed a sequential decline, suggesting ongoing operational challenges that could affect investor confidence and lead to stock price volatility.
- Legal Investigation Initiated: Prominent law firm Lowey Dannenberg is investigating potential violations of federal securities laws by Fulgent, which may expose the company to legal liabilities and financial repercussions.
- Investor Losses Attention: Investors who suffered losses in Fulgent securities are encouraged to participate in the investigation, potentially triggering further legal actions and impacting the company's reputation.
See More
Fulgent Genetics Under Investigation for Securities Violations
- Financial Performance Disclosure: Fulgent Genetics reported its 2025 fiscal year revenue at approximately $322.7 million on February 27, 2026, which slightly missed the previously updated guidance, indicating pressure in market competition.
- Quarterly Revenue Decline: The company experienced a sequential decline in fourth-quarter revenue, suggesting ongoing operational challenges that could impact investor confidence and lead to stock price volatility.
- Legal Investigation Initiated: Prominent law firm Lowey Dannenberg is investigating Fulgent for potential violations of federal securities laws, which may expose the company to legal liabilities and financial repercussions.
- Investor Losses Attention: Investors who suffered losses in Fulgent securities are encouraged to participate in the investigation, potentially triggering further legal actions and affecting the company's reputation.
See More
Fulgent Genetics Under Investigation for Securities Violations
- Financial Performance Disclosure: Fulgent Genetics reported approximately $322.7 million in revenue for the full year 2025, slightly missing the updated guidance, indicating pressure in market competition that could undermine investor confidence.
- Quarterly Revenue Decline: The company experienced a sequential decline in fourth-quarter revenue, highlighting ongoing operational challenges that may raise investor concerns about future performance and negatively impact stock price.
- Legal Investigation Initiated: Lowey Dannenberg P.C. is investigating Fulgent for potential violations of federal securities laws, and adverse findings could expose the company to legal liabilities and financial repercussions.
- Investor Losses Attention: Investors who suffered losses in Fulgent securities are encouraged to seek legal support from Lowey Dannenberg, indicating that the company's potential legal risks may further exacerbate market uncertainty.
See More
Fulgent Genetics Q1 2026 Earnings Call Insights
- Financial Overview: Fulgent Genetics reported Q1 2026 revenue of $71.1 million, slightly above analysts' expectations of $68.1 million, despite facing a decline in sales from its largest customer, indicating stability amidst challenges.
- Acquisition Impact: The successful acquisition of Bako Diagnostics and StrataDx contributed $2.6 million in revenue and more than doubled the size of the pathology sales team, which is expected to enhance market competitiveness and drive future growth through integration.
- Profitability Outlook: The company anticipates a non-GAAP gross margin of 39% for 2026, with expectations to improve to 42% by year-end, despite current pressures from decreased sales volume and claims processing backlog, reflecting management's confidence in restoring profitability.
- Future Guidance: Fulgent reiterated its total revenue guidance of $350 million for 2026, projecting an 8.5% year-over-year growth, while updating EPS expectations to reflect the impact of stock repurchases, indicating a cautiously optimistic outlook on future performance.
See More
Fulgent Genetics Reports Q1 Earnings Miss with Revenue Beat
- Earnings Performance: Fulgent Genetics reported a Q1 non-GAAP EPS of -$0.36, missing expectations by $0.01, indicating ongoing challenges in profitability.
- Revenue Insights: The company generated $71.1M in revenue, a 3.3% year-over-year decline, yet surpassed market expectations by $3.01M, suggesting a resilient market demand despite challenges.
- Gross Profit Analysis: GAAP gross profit stood at $21.5M with a gross margin of 30.2%, while non-GAAP gross profit was $23.0M with a gross margin of 32.3%, reflecting efforts in cost management.
- Future Outlook: Fulgent Genetics forecasts $350M in revenue for 2026, aiming for a 53% annual growth rate driven by acquisitions of Bako and StrataDx to reshape its customer mix.
See More
Fulgent Genetics Presents Updated Data at ASCO Meeting
- Clinical Trial Data Update: Fulgent Genetics presented updated data on FID-007 in combination with cetuximab at the 2026 ASCO Annual Meeting, revealing a 61.9% objective response rate in patients with recurrent or metastatic head and neck squamous cell carcinoma, indicating significant clinical activity in this target population.
- Survival Metrics: As of the April 16, 2026 data cutoff, the median progression-free survival was 6.7 months, median duration of response was 7.4 months, and one-year overall survival was 63.4%, providing crucial support for the clinical application of FID-007 and potentially altering treatment standards.
- Future Research Plans: Fulgent plans to conduct a Phase 3 study to further validate the efficacy and safety of the FID-007 and cetuximab combination, which may offer new hope for patients lacking effective second-line treatment options and holds significant market potential.
- Technological Platform Advantage: Fulgent's therapeutic development business focuses on developing cancer drugs using a novel nanoencapsulation and targeted therapy platform designed to improve therapeutic windows and pharmacokinetic profiles, highlighting the company's strategic transformation and innovation capabilities in precision medicine.
See More
Fulgent Genetics Under Investigation for Securities Violations
- Financial Performance Disclosure: Fulgent Genetics reported its 2025 fiscal year revenue at approximately $322.7 million on February 27, 2026, which slightly missed the updated guidance, indicating pressure in market competition.
- Quarterly Revenue Decline: The company's fourth-quarter revenue showed a sequential decline, suggesting ongoing operational challenges that could affect investor confidence and lead to stock price volatility.
- Legal Investigation Initiated: Prominent law firm Lowey Dannenberg is investigating potential violations of federal securities laws by Fulgent, which may expose the company to legal liabilities and financial repercussions.
- Investor Losses Attention: Investors who suffered losses in Fulgent securities are encouraged to participate in the investigation, potentially triggering further legal actions and impacting the company's reputation.
See More
Fulgent Genetics Under Investigation for Securities Violations
- Financial Performance Disclosure: Fulgent Genetics reported its 2025 fiscal year revenue at approximately $322.7 million on February 27, 2026, which slightly missed the previously updated guidance, indicating pressure in market competition.
- Quarterly Revenue Decline: The company experienced a sequential decline in fourth-quarter revenue, suggesting ongoing operational challenges that could impact investor confidence and lead to stock price volatility.
- Legal Investigation Initiated: Prominent law firm Lowey Dannenberg is investigating Fulgent for potential violations of federal securities laws, which may expose the company to legal liabilities and financial repercussions.
- Investor Losses Attention: Investors who suffered losses in Fulgent securities are encouraged to participate in the investigation, potentially triggering further legal actions and affecting the company's reputation.
See More
Fulgent Genetics Under Investigation for Securities Violations
- Financial Performance Disclosure: Fulgent Genetics reported approximately $322.7 million in revenue for the full year 2025, slightly missing the updated guidance, indicating pressure in market competition that could undermine investor confidence.
- Quarterly Revenue Decline: The company experienced a sequential decline in fourth-quarter revenue, highlighting ongoing operational challenges that may raise investor concerns about future performance and negatively impact stock price.
- Legal Investigation Initiated: Lowey Dannenberg P.C. is investigating Fulgent for potential violations of federal securities laws, and adverse findings could expose the company to legal liabilities and financial repercussions.
- Investor Losses Attention: Investors who suffered losses in Fulgent securities are encouraged to seek legal support from Lowey Dannenberg, indicating that the company's potential legal risks may further exacerbate market uncertainty.
See More
Fulgent Genetics Q1 2026 Earnings Call Insights
- Financial Overview: Fulgent Genetics reported Q1 2026 revenue of $71.1 million, slightly above analysts' expectations of $68.1 million, despite facing a decline in sales from its largest customer, indicating stability amidst challenges.
- Acquisition Impact: The successful acquisition of Bako Diagnostics and StrataDx contributed $2.6 million in revenue and more than doubled the size of the pathology sales team, which is expected to enhance market competitiveness and drive future growth through integration.
- Profitability Outlook: The company anticipates a non-GAAP gross margin of 39% for 2026, with expectations to improve to 42% by year-end, despite current pressures from decreased sales volume and claims processing backlog, reflecting management's confidence in restoring profitability.
- Future Guidance: Fulgent reiterated its total revenue guidance of $350 million for 2026, projecting an 8.5% year-over-year growth, while updating EPS expectations to reflect the impact of stock repurchases, indicating a cautiously optimistic outlook on future performance.
See More
Fulgent Genetics Reports Q1 Earnings Miss with Revenue Beat
- Earnings Performance: Fulgent Genetics reported a Q1 non-GAAP EPS of -$0.36, missing expectations by $0.01, indicating ongoing challenges in profitability.
- Revenue Insights: The company generated $71.1M in revenue, a 3.3% year-over-year decline, yet surpassed market expectations by $3.01M, suggesting a resilient market demand despite challenges.
- Gross Profit Analysis: GAAP gross profit stood at $21.5M with a gross margin of 30.2%, while non-GAAP gross profit was $23.0M with a gross margin of 32.3%, reflecting efforts in cost management.
- Future Outlook: Fulgent Genetics forecasts $350M in revenue for 2026, aiming for a 53% annual growth rate driven by acquisitions of Bako and StrataDx to reshape its customer mix.
See More
